| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4273350 | The Journal of Sexual Medicine | 2007 | 11 Pages |
Abstract
While the recent data supporting the therapeutic use of centrally acting agents as a monotherapy for FSD are cautiously encouraging, there would seem to be tremendous promise for these centrally acting compounds to be integrated with treatment approaches that utilize other pathways in a multilayered, individualized approach to care. Perelman MA. Clinical application of CNS-acting agents in FSD.
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Michael A. PhD,